Sort   by:  
 Page size 
MetabolomicsGut microbiome dysbiosis drives metabolic dysfunction in Familial dysautonomia
Familial dysautonomia (FD) is a rare genetic neurologic disorder caused by impaired neuronal development and progressive degeneration of both the peripheral and central nervous systems. FD is monogenic, with >99.4% of patients sharing an identical point mutation in the elongator acetyltransferase co...
2022-12-06 | MTBLS5138 | MetaboLights
ProteomicsHuman plasma LC-MS/MS from children with bacterial and viral infections
LC-MS/MS proteomic profiling was performed on children with bacterial and viral infections using plasma samples. Protein biomarkers indiciative of bacterial or viral infection were identified.
ORGANISM(S): Homo sapiens (Human) 
2023-11-14 | PXD041960 | Pride
Viral Bacterial Plasma Humans Lc-ms/ms 
ProteomicsHuman plasma LC-MS/MS from children with bacterial and viral infections
LC-MS/MS proteomic profiling was performed on children with bacterial and viral infections using plasma samples. Protein biomarkers indiciative of bacterial or viral infection were identified.
ORGANISM(S): Homo sapiens (Human) 
2023-11-14 | PXD042003 | Pride
Lc-ms/ms Human Plasma 
GenomicsBRCA_SNV_SR - samples
single nucleotide variant calls from somatic sniper, vcf format. input for subclonal reconstruction
EGAD00001003753 | EGA
GenomicsCPCG BRCA2 - samples
Aligned sequence data from 14 Prostate cancer samples with BRCA2 mutations
EGAD00001002739 | EGA
GenomicsCPCG-BRCA-ARRAY
Raw Array data from the CPCGene BRCA study
EGAD00010001196 | EGA
GenomicsBRCA_SNV - samples
single nucleotide variant calls from somatic sniper, vcf format
EGAD00001003752 | EGA
GenomicsBRCA_SV - samples
structural variant calls from Delly, vcf format
EGAD00001003754 | EGA
GenomicsMED12L Gene Alterations Define Aggressive BRCA2-Mutant Prostate Cancers
Germline mutation of BRCA2 increases the lifetime risk of developing prostate cancer (PCa) by over 700%. BRCA2-mutant PCa have poorer prognosis than sporadic PCa, with rapid development of metastatic, castrate-resistant prostate cancer (mCRPC) and 5-year cancer-specific survival rates of ~50-60%1-4....
EGAS00001001615 | EGA
TranscriptomicsWhole genome characterisation of chemoresistant ovarian cancer [NanoString miRNA]
Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-...
ORGANISM(S): Homo sapiens 
2015-05-19 | E-GEOD-65819 | biostudies-arrayexpress
Sort   by:  
 Page size